Skip to main content
. 2021 Dec 15;131(24):e147031. doi: 10.1172/JCI147031

Figure 6. Effect of circEsyt2 overexpression in HASMCs.

Figure 6

(A and B) Efficacy (A) and specificity (B) of circEsyt2 overexpression plasmid detected by qRT-PCR and Western blotting in HASMCs. **P < 0.01 vs. pcDNA3.1. n = 3. (C) CCK-8 assay of circEsyt2-overexpressed (OE) HASMCs for the indicated hours. *P < 0.05 vs. pcDNA3.1. n = 4. (D) EdU incorporation assay of HASMCs, treated as in C for 48 hours. Left: representative immunofluorescence staining for EdU (red) and DAPI (blue). Scale bars: 100 μm. Right: percentages of EdU incorporated-HASMCs. **P < 0.01 vs. pcDNA3.1. n = 3. (E and F) Migratory ability assessed by wound healing (E) and Transwell assay (F) of circEsyt2-OE HASMCs. Scale bars: 100 μm. *P < 0.05 vs. pcDNA3.1. n = 3. (G) Apoptosis detected by Annexin V–conjugated flow cytometry of circEsyt2-OE HASMCs. *P < 0.05 vs. pcDNA3.1. n = 3. (H) Western blotting to check the expression of α-SMA, Calponin, and Myh11 in circEsyt2-OE HASMCs. **P < 0.01 vs. pcDNA3.1. n = 3. Two-sided unpaired t test for A, B, and D–H. Two-way repeated measures ANOVA with Bonferroni’s post hoc test for C.